Filtered By:
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie
Drug: Zyprexa
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway
This study investigated whether apolipoprotein A5 (apoA5) and sortilin, two interactive factors involved in NAFLD pathogenesis, are implicated in olanzapine-induced NAFLD. In our study, at week 8, olanzapine treatment successfully induced hepatic steatosis in female C57 BL/6 J mice, which was independent of body weight gain. Likewise, olanzapine effectively mediated hepatocyte steatosis in HepG2 cells characterized by substantially elevated intracellular lipid droplets. Increased plasma triglyceride concentration and decreased plasma apoA5 levels were observed in mice treated with 8-week olanzapine. Surprisingly, olanzapin...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 19, 2021 Category: Drugs & Pharmacology Authors: Rong Li Wenqiang Zhu Piaopiao Huang Yang Yang Fei Luo Wen Dai Li Shen Wenjing Pei Xiansheng Huang Source Type: research
